Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
10x Research: The market is entering a critical turning point, with models favoring an altcoin season

10x Research: The market is entering a critical turning point, with models favoring an altcoin season

Odaily星球日报Odaily星球日报2026/03/20 07:13
Show original

Odaily reported that 10x Research released a market analysis indicating that bitcoin is currently maintaining a key support level, but altcoins have gradually taken the lead, creating a risk of position misallocation in the market.

The analysis stated that the market is at a critical turning point, and trading profits now rely more on tactical position adjustments rather than simply directional judgment. The model shows that, with bitcoin dominance declining, altcoins are expected to perform better.

The report also pointed out that the pressure from token unlocks has eased and low trading volumes reflect limited selling pressure, providing some support to the market. Meanwhile, bitcoin faces macroeconomic pressure and ETF outflows, while ethereum is supported by institutional accumulation and structural upgrades.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08

Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000

PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.

智通财经•2026/10/09 06:47